WRAL Tech Wire

DataSpectrum Opens Office in U.K.

Week in Review: Region's Roller Coaster Ride Continues

We're up, we're down, we're holding on for dear life - last week saw a mix of highs and lows for the Carolinas and Georgia.

Quintiles to Market Women's Health Care Products for Columbia Labs

Burned by the Market: BellSouth Leads Way But Has Plenty of Company

A 'Top 10' list of losers from Georgia shows $42.45B loss in market capitalization. North Carolina's 'Top 10' sheds $14B of $27.3 in value.

Week in Review: A New CEO is the Must-Have Accessory for Q3

Changes in the executive suite dominate the news. Sales and acquisitions make headlines, too. An interesting investment deal highlights a slow week of venture moves.

Quintiles To Help Lilly Market New Depression Treatment

Quintiles Beats Estimates in 2Q

Herd on the Street: Biotech Is 'Flavor of the Month' For the VCs

Burned by IT flameouts in recent years, some major regional VC players are shifting their focus to funding biotechnology startups. At least two other funds are starting with a biotech-only premise.

Venture Profile: Thompson Clive Venture Capital Has an Eye on Triangle

Firm, which opened Raleigh office in 2001, insists on being selective, looks for second-round and later deals up to $3 million in size.

RTP Investor Relations Group Gets Charter

Aurora Puts Part of New Fund in Pittsburgh Bioinformatics Firm

Durham VCs join $12.5 million round for TissueInformatics. Aurora sees startup's technology as huge advance for tissue analysis.

Raleigh Clinical Trials Firm Lands $11 Million in New Funding

INC Research, which focuses on oncology and central nervous system drugs, looks to expand into Europe and build its data management division. Crosspoint Venture leads round.

Verispan - Quintiles' New Joint Venture - Gets Underwa y

North Carolina Can Help Lead War Against Bio-Terror, Burr Says

Rep. Richard Burr (R-NC) to tell Biotech 2002 audience that NC is in a "tremendous position" to profit from and to lead the national effort to shore up its defenses.

Quintiles Changes 2 on Board